Cardiology
CHF
More in CHF
Standard of care prevails in single-center trial
More patients taking sodium zirconium cyclosilicate achieved normokalemia vs placebo recipients
Benefit shown in trial of patients flagged for high risk of cardiotoxicity
Time for "long goodbye" to the "burning red devil," say editorialists
Recent developments of interest in cardiovascular medicine
Intranasal bumetanide demonstrated safety, bioequivalence with its oral and IV counterparts
Phase II trial does hold a few signals that might warrant another attempt
Phase I results show "big improvement" for what is usually progressive hypertrophy, expert says
AI transformation of the way cardiology uses echo "is absolutely going to happen, expert says
Japanese trial supports use but event risk might be low enough to suggest a different strategy
One-time treatment with nexiguran ziclumeran tied to decline in serum TTR levels in phase I trial
SUMMIT trial able to show clinical benefit beyond quality-of-life improvement
Recent developments of interest in cardiovascular medicine
Researchers try to address challenge of distinguishing HCM from other cardiomyopathies
